News

BarentsKrans acts as independent advisor in relation to the investment in NewCompliance

BarentsKrans has acted as independent advisor for NewCompliance B.V., its founders and investors InnovationQuarter and Noaber Ventures during this transaction. BarentsKrans often acts as independent advisor in order to ensure that the transaction process is efficient and smooth. The scale-up NewCompliace has obtained an investment of USD 3 million to finance its expansion to the
Read more ›

The Dutch Authority for the Financial Markets (AFM) and the Dutch Central Bank (DNB) identify best practices for alternative interest rate benchmarks

From 1 January 2022 onwards, the Benchmark Regulation (2016/1011/EU) will be directly applicable in each member state of the European Union. As a result, certain crucial interest rate benchmarks, such as EURIBOR, LIBOR and EONIA, shall not be admissible in its current form. From that point on, new financial agreements and, in principle, also existing
Read more ›

Telecoms update: ‘Better Network’ campaign KPN not unlawful, rules District Court

Our Telecoms Update of 30 July 2019 is about the recent decision of the The Hague District Court in KPN v T-Mobile. The Court ruled that KPN’s advertising campaign ‘Better Network, Better Life’ did not constitute unlawful comparative advertising and rejected T-Mobile claims in full. The judgment means that KPN is allowed to continue its very successful advertising campaign. BarentsKrans represented KPN in this case.
Read more ›

Pharma update: pemetrexed tromethamine does not infringe pemetrexed disodium patent

In its judgment of 19 June 2019, the District Court of The Hague ruled that Fresenius Kabi’s pemetrexed tromethamine falls outside the scope of protection of Eli Lilly’s patent for pemetrexed disodium. This final relief decision deviates from earlier decisions in interim relief proceedings and decisions by several foreign courts. Eli Lilly (“Lilly”) markets the
Read more ›